Natixis Adaptive Biotechnologies Corp Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$6.4 - $14.73 $1.01 Million - $2.32 Million	-157,474 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$10.12 - $28.9 $1.59 Million - $4.55 Million	157,474 New	157,474 $2.19 Million
Q4 2021 Feb 14, 2022	SELL	$25.17 - $36.85 $148,628 - $217,599	-5,905 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$30.02 - $39.87 $1,410 - $1,873	-47 Reduced 0.79%	5,905 $201,000
Q2 2021 Aug 13, 2021	SELL	$32.22 - $44.59 $2 Million - $2.77 Million	-62,122 Reduced 91.26%	5,952 $243,000
Q1 2021 May 14, 2021	BUY	$37.26 - $67.74 $1.56 Million - $2.84 Million	41,874 Added 159.82%	68,074 $2.74 Million
Q4 2020 Feb 12, 2021	SELL	$45.01 - $65.47 $1.64 Million - $2.38 Million	-36,380 Reduced 58.13%	26,200 $1.55 Million
Q3 2020 Nov 12, 2020	BUY	$35.79 - $48.81 $2.24 Million - $3.05 Million	62,580 New	62,580 $3.04 Million

204

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $929M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.